Increased disease activity in early arthritis patients with anti-carbamylated protein antibodies

Abstract The initial management of rheumatoid arthritis (RA) has a high impact on disease prognosis. Therefore, we need to select the most appropriate treatment as soon as possible. This goal requires biomarkers of disease severity and prognosis. One such biomarker may be the presence of anti-carbam...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cristina Regueiro, Laura Nuño, Ana Triguero-Martinez, Ana M. Ortiz, Alejandro Villalba, María Dolores Bóveda, Ana Martínez-Feito, Carmen Conde, Alejandro Balsa, Isidoro González-Alvaro, Antonio Gonzalez
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b6491be058124b308159c5caeeafb49e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b6491be058124b308159c5caeeafb49e
record_format	dspace
spelling	oai:doaj.org-article:b6491be058124b308159c5caeeafb49e2021-12-02T17:01:43ZIncreased disease activity in early arthritis patients with anti-carbamylated protein antibodies10.1038/s41598-021-89502-y2045-2322https://doaj.org/article/b6491be058124b308159c5caeeafb49e2021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-89502-yhttps://doaj.org/toc/2045-2322Abstract The initial management of rheumatoid arthritis (RA) has a high impact on disease prognosis. Therefore, we need to select the most appropriate treatment as soon as possible. This goal requires biomarkers of disease severity and prognosis. One such biomarker may be the presence of anti-carbamylated protein antibodies (ACarPA) because it is associated with adverse long term outcomes as radiographic damage and mortality. Here, we have assessed the ACarPA as short-term prognostic biomarkers. The study was conducted in 978 prospective early arthritis (EA) patients that were followed for two years. Our results show the association of ACarPA with increased levels of all the disease activity measures in the first visit after arthritis onset. However, the associations were more significant with the high levels in local measures of inflammation and physician assessment than with the increases in systemic inflammation and patient-reported outcomes. More notably, disease activity was persistently increased in the ACarPA positive patients during the two years of follow-up. These differences were significant even after accounting for the presence of other RA autoantibodies. Therefore, the ACarPA could be considered short-term prognostic biomarkers of increased disease activity in the EA patients.Cristina RegueiroLaura NuñoAna Triguero-MartinezAna M. OrtizAlejandro VillalbaMaría Dolores BóvedaAna Martínez-FeitoCarmen CondeAlejandro BalsaIsidoro González-AlvaroAntonio GonzalezNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Cristina Regueiro Laura Nuño Ana Triguero-Martinez Ana M. Ortiz Alejandro Villalba María Dolores Bóveda Ana Martínez-Feito Carmen Conde Alejandro Balsa Isidoro González-Alvaro Antonio Gonzalez Increased disease activity in early arthritis patients with anti-carbamylated protein antibodies
description	Abstract The initial management of rheumatoid arthritis (RA) has a high impact on disease prognosis. Therefore, we need to select the most appropriate treatment as soon as possible. This goal requires biomarkers of disease severity and prognosis. One such biomarker may be the presence of anti-carbamylated protein antibodies (ACarPA) because it is associated with adverse long term outcomes as radiographic damage and mortality. Here, we have assessed the ACarPA as short-term prognostic biomarkers. The study was conducted in 978 prospective early arthritis (EA) patients that were followed for two years. Our results show the association of ACarPA with increased levels of all the disease activity measures in the first visit after arthritis onset. However, the associations were more significant with the high levels in local measures of inflammation and physician assessment than with the increases in systemic inflammation and patient-reported outcomes. More notably, disease activity was persistently increased in the ACarPA positive patients during the two years of follow-up. These differences were significant even after accounting for the presence of other RA autoantibodies. Therefore, the ACarPA could be considered short-term prognostic biomarkers of increased disease activity in the EA patients.
format	article
author	Cristina Regueiro Laura Nuño Ana Triguero-Martinez Ana M. Ortiz Alejandro Villalba María Dolores Bóveda Ana Martínez-Feito Carmen Conde Alejandro Balsa Isidoro González-Alvaro Antonio Gonzalez
author_facet	Cristina Regueiro Laura Nuño Ana Triguero-Martinez Ana M. Ortiz Alejandro Villalba María Dolores Bóveda Ana Martínez-Feito Carmen Conde Alejandro Balsa Isidoro González-Alvaro Antonio Gonzalez
author_sort	Cristina Regueiro
title	Increased disease activity in early arthritis patients with anti-carbamylated protein antibodies
title_short	Increased disease activity in early arthritis patients with anti-carbamylated protein antibodies
title_full	Increased disease activity in early arthritis patients with anti-carbamylated protein antibodies
title_fullStr	Increased disease activity in early arthritis patients with anti-carbamylated protein antibodies
title_full_unstemmed	Increased disease activity in early arthritis patients with anti-carbamylated protein antibodies
title_sort	increased disease activity in early arthritis patients with anti-carbamylated protein antibodies
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/b6491be058124b308159c5caeeafb49e
work_keys_str_mv	AT cristinaregueiro increaseddiseaseactivityinearlyarthritispatientswithanticarbamylatedproteinantibodies AT lauranuno increaseddiseaseactivityinearlyarthritispatientswithanticarbamylatedproteinantibodies AT anatrigueromartinez increaseddiseaseactivityinearlyarthritispatientswithanticarbamylatedproteinantibodies AT anamortiz increaseddiseaseactivityinearlyarthritispatientswithanticarbamylatedproteinantibodies AT alejandrovillalba increaseddiseaseactivityinearlyarthritispatientswithanticarbamylatedproteinantibodies AT mariadoloresboveda increaseddiseaseactivityinearlyarthritispatientswithanticarbamylatedproteinantibodies AT anamartinezfeito increaseddiseaseactivityinearlyarthritispatientswithanticarbamylatedproteinantibodies AT carmenconde increaseddiseaseactivityinearlyarthritispatientswithanticarbamylatedproteinantibodies AT alejandrobalsa increaseddiseaseactivityinearlyarthritispatientswithanticarbamylatedproteinantibodies AT isidorogonzalezalvaro increaseddiseaseactivityinearlyarthritispatientswithanticarbamylatedproteinantibodies AT antoniogonzalez increaseddiseaseactivityinearlyarthritispatientswithanticarbamylatedproteinantibodies
_version_	1718382047602409472

Increased disease activity in early arthritis patients with anti-carbamylated protein antibodies

Ejemplares similares